Introduction
Controlled trials have repeatedly shown that carbenoxolone sodium promotes the healing of gastric ulcers and that side effects of fluid retention and electrolyte disturbance occur often enough to limit the freedom with which the drug can be used (Doll et al., 1968; Turpie and Thomson, 1965) . Another compound, gefarnate (geranyl farnesylacetate), is claimed to be free of such side effects and, from uncontrolled studies and two limited controlled trials, to promote gastric ulcer healing (da Grada et al., 1967; Giovanelli, 1963; Necomb et al., 1970) . We have therefore compared directly the clinical efficacy of gefarnate with that of carbenoxolone sodium.
Gefarnate is a terpene which contains a number of isoprene units, the basic fragments, from which pentacyclic ring structures like steroids can be synthesized and with which the triterpenoid, carbenoxolone, bears some structural resemblances. Nevertheless, carbenoxolone has a relatively fixed steric form whereas gefarnate is conformationally mobile, and structural resemblances may be more apparent than real (see formulae).
Patients and Method
Patients under the age-of 70 years with gastric ulcers thought suitable for outpatient treatment were referred to a special clinic and barium-meal examination was carried out on the same day. They were then included in the trial unless (1) the ulcer had healed, the area was difficult to measure, or was less than 10 mm2 when measured in maximum profile; (2) a second gastric ulcer was present; or (3) there were clinical reasons such as hypertension, heart disease, or suspicion of malignancy which made inclusion in the trial undesirable. The number of patients referred was 128, and 55 of them were excluded for various reasons (table I) 
Structures of carbenoxolone and gefarnate. (table IV) , and this difference from gefarnate was highly significant (P <0 01). (Newcomb et al., 1970) . We have preferred to use the yardstick of a well-proved medical treatment, carbenoxolone, against which to measure the value of gefarnate, and our results do not necessarily imply that gefarnate is valueless.
In our study ulcers healed on average by 80'6% and 51-7% respectively when taken overall in patients receiving carbenoxolone and gefarnate, a ratio of 1:0-64. By contrast, in two previous controlled comparisons between carbenoxolone and placebo treatments, conducted in an almost identical manner to our own, healing with carbenoxolone and placebo averaged 72% and 35% and 78% and 39% (Doll et al., 1962 (Doll et al., , 1965 , yielding ratios of 1:0-49 and 1:0-50 respectively. The lower ratio of 1 :0-64 obtained by us with gefarnate and carbenoxolone therefore suggests that gefarnate may have some, if weaker, healing properties than carbenoxolone.
Interpretation of the healing responses to the three different dose levels of gefarnate is difficult. The apparent increase in effectiveness with a rise from 200 to 400 mg daily was due in part to the effect of a single ulcer in the low dose group which increased markedly in size during treatment. Exclusion of this figure from consideration would raise overall healing in the low dose group from 37 to 62%-nearly the same as the figures obtained with the middle dose of gefarnate. The absence of any incremental response to a further doubling of gefarnate dose argues that any effect of the drug is probably maximal at 400 mg daily, and this should probably be used in any future clinical studies. If the apparent lack of side effects with gefarnate is taken into account possibly the drug may have a limited place in the treatment of gastric ulcers in the elderly or in those with cardiorespiratory disease who are particularly prone to fluid retention. Introduction A possible therapeutic measure to reduce liver damage after an overdose of paracetamnol (Proudfoot and Wright, 1970; Clark et al., 1973) would be the slowing of the absorption of the drug from the gastrointestinal tract. Oral administration of activated charcoal decreases the absorption of aspirin (Levy and Tsuchiya, 1972) , while the anion-exchange resin cholestyramine also decreases the intestinal absorption of some drugs (Gabo et al., 1965) . Our in vitro experiments indicated that paracetamol was firmly bound by both of these adsorbents, and we therefore decided to investigate their efficacy in man in slowing the absorption of paracetamol from the gastrointestinal tract.
The presumptive absorption of a therapeutic dose of paracetamol in normal subjects was first studied by measuring plasma levels of the drug after an oral dose and then noting the effect on these of activated charcoal and cholestyramine given by mouth at two diffierent times. We also measured the presumptive rate of absorption in patients who had previously taken an overdose of paracetamol to determine whether differences in absorption were responsible for the variable degrees of hepatic damage observed in these patients.
Methods
Normal subjects and patients were fasted overnight. Venous blood samples were taken 5, 10, 20, 40, 60, and 120 minutes after ingestion of 2 g paracetanol with 200 ml water. The plasma concentration of paracetamol was determined as follows: 0 5 ml plasma was added to stoppered test-tubes containing 300 mg sodium chloride, 10 ml of diethyl ether (Analar) was added, and the tubes were shaken by hand for 30 seconds. After centrifugation at a maximum of 1,300 g for 10 minutes the upper phase was removed and the absorbence at 250 nm determined. Recovery of standard amounts of paracetamol from plasma by ether extraction was greater than 90%, and after calibration there was no significant difference between values obtained with five paired samples measured both by this spectroscopic method and by gas-liquid chromatography. The plasma paracetamol concentrations were plotted against time, and by using the trapezoidal rule the area under the curves was calculated as an estimate of the amount absorbed. Student's t test was used for assessment of statistical significance.
Results
The mean plasma absorption curve of paracetamol in 14 normal subjects is shown in fig. 1 . The drug was rapidly absorbed, with peak plasma levels at 40 to 60 minutes. The concentrations at that time ranged from 18 to 87 i&g/ml. The absorption of paracetamol was then restudied in these subjects under the same conditions but for the addition of activated charcoal or cholestyramine. Seven subjects ingested 10 g charcoal given as a suspension in methylcellulose (20 g/100 ml) immediately after the paracetamol. Mean plasma paracetamol levels were considerably lower ( fig. 1) , with a 63 + 7% (mean ± S.E. of mean; range 32-87%) reduction in absorption measured as the 
